SELF SCORED CARDIOVASCULAR DISEASES RISK APPRAISAL

自评分心血管疾病风险评估

• 批准号: 2423724
• 负责人: KEVIN W SMITH
• 金额: $ 25.94万
• 依托单位: NEW ENGLAND RESEARCH INSTITUTES, INC.
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-30 至 1999-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2423724
• 关键词: cardiovascular disorder; clinical research; disease /disorder proneness /risk; human morbidity; human mortality; human subject; method development; questionnaires

Health risk appraisals (HRA) are being used increasingly by health centers and worksites to inform people of their personal mortality and morbidity risks. However, recent research suggests that many HRAs have limited reliability and validity with respect to coronary heart disease, the leading cause of death in this country. Self-scored HRAs appear to be considerably less accurate in predicting CHD risk than computerized instruments, chiefly because people do not always know the physiologic values required by these instruments and because they frequently make errors computing their scores. During Phase I, a new appraisal named CardioRisk was developed. The Phase I prototype version contains eight major self-reported risk factors. CardioRisk predicts the risk of developing cardiovascular disease (CVD) in a 12-year period using an equation based on recent accelerated failure time models from the Framingham Heart Study. The purpose of Phase II is to thoroughly test and refine the prototype instrument. The Phase II analyses are designed to assess the psychometric properties of CardioRisk, to evaluate its utility as judged by patients, and to determine whether the instrument changes perceptions of personal CVD risk. These results will be compared to data for other appraisals to determine whether CardioRisk outperforms comparable products. PROPOSED COMMERCIAL APPLICATION: CardioRisk would be distributed by health promotion organizations to increase awareness of the risk factors for cardiovascular disease. Estimates from the American Heart Association put the demand for these products at 180,000 HRAs per year. The potential market for this product includes worksites, community health centers, managed health care organizations, public health departments, and clinics.

健康风险评估(HRA)正被越来越多的健康人士使用 中心和工作地点，以告知人们他们的个人死亡和 发病风险。然而，最近的研究表明，许多HRA 关于冠心病的可靠性和有效性有限， 是这个国家的头号死因。自我评分的HRA似乎 在预测冠心病风险方面远不如计算机化准确 仪器，主要是因为人们并不总是知道生理 这些工具所需的值，因为它们经常使 计算他们的分数时出错。在第一阶段，一项名为 研发出了心脏风险系统。第一阶段原型版本包含八个 主要的自我报告风险因素。心脏风险预测的风险 在12年内使用 基于最近的加速失效时间模型的方程 弗雷明翰心脏研究。第二阶段的目的是彻底测试 并对样机进行了改进。设计了第二阶段分析 评估心脏风险的心理测量学特性，以评估其 实用性由患者判断，并确定该仪器是否 改变了人们对个人心血管疾病风险的看法。这些结果将被比较 用于其他评估的数据，以确定心脏风险是否优于 可比产品。 建议的商业应用： 心脏风险将由健康促进组织分发给 提高对心血管疾病风险因素的认识。 美国心脏协会的估计显示，对这些产品的需求 每年生产180,000个HRA产品。这种产品的潜在市场 包括工作场所、社区医疗中心、管理型医疗保健 组织、公共卫生部门和诊所。